Literature DB >> 22708092

Castleman's Disease with Myasthenia Gravis.

Sang-Kwon Lee1, Do-Hyung Kim, Bong Soo Son.   

Abstract

Castleman's disease is a rare disorder characterized by benign tumors that may develop in the lymph node tissue throughout the body. Castleman's disease associated with myasthenia gravis is an especially rare disease. Only less than 10 cases have been reported in the world literature. The cause of Castleman's disease is associated with immune mediated reaction, and myasthenia gravis also develops due to an antibody-mediated process. The cause of myasthenia gravis is the immune activity of Castleman's disease, which may be the promoter of the antibody-mediated process. We report here a case of Castleman's disease, which was incidentally found in a patient diagnosed with myasthenia gravis.

Entities:  

Keywords:  Myasthenia gravis; Retroperitoneal neoplasms; Thymectomy

Year:  2012        PMID: 22708092      PMCID: PMC3373980          DOI: 10.5090/kjtcs.2012.45.3.199

Source DB:  PubMed          Journal:  Korean J Thorac Cardiovasc Surg        ISSN: 2233-601X


  7 in total

Review 1.  Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans.

Authors:  T Chorzelski; T Hashimoto; B Maciejewska; M Amagai; G J Anhalt; S Jablonska
Journal:  J Am Acad Dermatol       Date:  1999-09       Impact factor: 11.527

Review 2.  Castleman's disease.

Authors:  H Shahidi; J L Myers; P A Kvale
Journal:  Mayo Clin Proc       Date:  1995-10       Impact factor: 7.616

3.  Castleman's disease associated with myasthenia gravis.

Authors:  Jonathan R S Day; Duncan Bew; Mark Ali; Roberto Dina; Peter L C Smith
Journal:  Ann Thorac Surg       Date:  2003-05       Impact factor: 4.330

4.  Extrathoracic angiofollicular lymphoid hyperplasia with coincidental myasthenia gravis.

Authors:  H E Emson
Journal:  Cancer       Date:  1973-01       Impact factor: 6.860

Review 5.  Neuromuscular junction channelopathies: a brief overview.

Authors:  John Newsom-Davis
Journal:  Acta Neurol Belg       Date:  2005-12       Impact factor: 2.396

6.  Multicentric angiofollicular lymph-node hyperplasia associated with myasthenia gravis.

Authors:  I Paşaoğlu; R Doğan; M Topçu; Y Güngen
Journal:  Thorac Cardiovasc Surg       Date:  1994-08       Impact factor: 1.827

Review 7.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05
  7 in total
  6 in total

1.  Sjögren's and plasma cell variant Castleman disease: a case report.

Authors:  Yvonne A Dei-Adomakoh; Leslie Quarcoopome; Afua D Abrahams; Catherine I Segbefia; Dzifa I Dey
Journal:  Ghana Med J       Date:  2018-03

2.  Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases.

Authors:  Dao-Ping Sun; Wen-Ming Chen; Li Wang; Zhen Wang; Jin-Hua Liang; Hua-Yuan Zhu; Lei Fan; Yu-Jie Wu; Wei Xu; Jian-Yong Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

3.  A case report of retroperitoneal pararenal Castleman's disease associated with myasthenia gravis.

Authors:  Shuai Wang; Shan-Wen Chen; Song-Liang Cai; Bai-Yan Jin
Journal:  World J Surg Oncol       Date:  2014-11-07       Impact factor: 2.754

4.  A Case Report of Subclinical Myasthenia Gravis Associated with Castleman's Disease.

Authors:  Tuqa Adil Alsinan; Hassan Ahmad Robaidi; Waleed Neamatallah Saleh
Journal:  Am J Case Rep       Date:  2021-06-11

5.  Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura.

Authors:  Ruchi Sood; Harris C Taylor; Hamed Daw
Journal:  Case Rep Hematol       Date:  2013-10-02

6.  Tocilizumab-resistant TAFRO Syndrome Complicated by Type II Respiratory Failure.

Authors:  Tatsuya Aoki; Mikio Wada; Atsushi Kawashima; Kouichi Hirakawa; Akihiro Nagata; Keizo Kagawa
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.